Cargando…
Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV
Infection with hepatitis C virus (HCV) does not induce protective immunity, and re-exposure to HCV can reinfect the population engaging in high-risk behavior. An increasing incidence of acute hepatitis C infection in people living with HIV (PLWH) has been described in recent years. This retrospectiv...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874599/ https://www.ncbi.nlm.nih.gov/pubmed/35216032 http://dx.doi.org/10.3390/v14020439 |
_version_ | 1784657727155339264 |
---|---|
author | Cheng, Chien-Yu Ku, Shin-Yen Lin, Yi-Chun Chen, Cheng-Pin Cheng, Shu-Hsing Lin, I-Feng |
author_facet | Cheng, Chien-Yu Ku, Shin-Yen Lin, Yi-Chun Chen, Cheng-Pin Cheng, Shu-Hsing Lin, I-Feng |
author_sort | Cheng, Chien-Yu |
collection | PubMed |
description | Infection with hepatitis C virus (HCV) does not induce protective immunity, and re-exposure to HCV can reinfect the population engaging in high-risk behavior. An increasing incidence of acute hepatitis C infection in people living with HIV (PLWH) has been described in recent years. This retrospective cohort study was conducted in PLWH who completed HCV therapy between June 2009 and June 2020 at an HIV care hospital, to analyze their basic characteristics and risky behavior. Of 2419 patients, 639 were diagnosed with HCV infection and 516 completed the HCV therapy with a sustained virologic response. In total, 59 patients (11.4%) were reinfected with acute hepatitis C, and the median time to reinfection was 85.3 weeks (IQR: 57–150). The incidence of reinfection was 6.7 cases/100 person-years. The factors associated with reinfection were being male (AHR, 8.02; 95% CI 1.08–59.49), DAA (direct-acting antiviral) treatment (AHR, 2.23; 95% CI 1.04–4.79), liver cirrhosis (AHR, 3.94; 95% CI 1.09–14.22), heroin dependency (AHR: 7.41; 95% CI 3.37–14.3), and HIV viral loads <50 copies/mL at the follow-up (AHR: 0.47, 95% CI 0.24–0.93) in the subgroup of people who inject drugs (PWID). Amphetamine abuse (AHR: 20.17; 95% CI 2.36–172.52) was the dominant factor in the subgroup of men who have sex with men (MSM). Our study suggests that education and behavioral interventions are needed in this population to prevent reinfection. |
format | Online Article Text |
id | pubmed-8874599 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88745992022-02-26 Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV Cheng, Chien-Yu Ku, Shin-Yen Lin, Yi-Chun Chen, Cheng-Pin Cheng, Shu-Hsing Lin, I-Feng Viruses Article Infection with hepatitis C virus (HCV) does not induce protective immunity, and re-exposure to HCV can reinfect the population engaging in high-risk behavior. An increasing incidence of acute hepatitis C infection in people living with HIV (PLWH) has been described in recent years. This retrospective cohort study was conducted in PLWH who completed HCV therapy between June 2009 and June 2020 at an HIV care hospital, to analyze their basic characteristics and risky behavior. Of 2419 patients, 639 were diagnosed with HCV infection and 516 completed the HCV therapy with a sustained virologic response. In total, 59 patients (11.4%) were reinfected with acute hepatitis C, and the median time to reinfection was 85.3 weeks (IQR: 57–150). The incidence of reinfection was 6.7 cases/100 person-years. The factors associated with reinfection were being male (AHR, 8.02; 95% CI 1.08–59.49), DAA (direct-acting antiviral) treatment (AHR, 2.23; 95% CI 1.04–4.79), liver cirrhosis (AHR, 3.94; 95% CI 1.09–14.22), heroin dependency (AHR: 7.41; 95% CI 3.37–14.3), and HIV viral loads <50 copies/mL at the follow-up (AHR: 0.47, 95% CI 0.24–0.93) in the subgroup of people who inject drugs (PWID). Amphetamine abuse (AHR: 20.17; 95% CI 2.36–172.52) was the dominant factor in the subgroup of men who have sex with men (MSM). Our study suggests that education and behavioral interventions are needed in this population to prevent reinfection. MDPI 2022-02-21 /pmc/articles/PMC8874599/ /pubmed/35216032 http://dx.doi.org/10.3390/v14020439 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cheng, Chien-Yu Ku, Shin-Yen Lin, Yi-Chun Chen, Cheng-Pin Cheng, Shu-Hsing Lin, I-Feng Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV |
title | Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV |
title_full | Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV |
title_fullStr | Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV |
title_full_unstemmed | Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV |
title_short | Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV |
title_sort | incidence and risk factors of reinfection with hcv after treatment in people living with hiv |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874599/ https://www.ncbi.nlm.nih.gov/pubmed/35216032 http://dx.doi.org/10.3390/v14020439 |
work_keys_str_mv | AT chengchienyu incidenceandriskfactorsofreinfectionwithhcvaftertreatmentinpeoplelivingwithhiv AT kushinyen incidenceandriskfactorsofreinfectionwithhcvaftertreatmentinpeoplelivingwithhiv AT linyichun incidenceandriskfactorsofreinfectionwithhcvaftertreatmentinpeoplelivingwithhiv AT chenchengpin incidenceandriskfactorsofreinfectionwithhcvaftertreatmentinpeoplelivingwithhiv AT chengshuhsing incidenceandriskfactorsofreinfectionwithhcvaftertreatmentinpeoplelivingwithhiv AT linifeng incidenceandriskfactorsofreinfectionwithhcvaftertreatmentinpeoplelivingwithhiv |